We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

7 hedge funds and large institutions have $84.9K invested in ZyVersa Therapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

17% more funds holding

Funds holding: 6 → 7 (+1)

1.08% less ownership

Funds ownership: 1.23% → 0.15% (-1.1%)

53% less capital invested

Capital invested by funds: $181K → $84.9K (-$96.6K)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CSS
Cubist Systematic Strategies
Connecticut
+$22.1K
2
UBS Group
UBS Group
Switzerland
+$12.5K
3
HF
HRT Financial
New York
+$9.93K
4
TSS
Two Sigma Securities
New York
+$9.45K
5
Jane Street
Jane Street
New York
+$9.13K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$145K
2
Citadel Advisors
Citadel Advisors
Florida
-$13.5K

ZVSA Hedge Fund Activity: Q1 2024 in Review

7 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q1 2024, worth a combined $84.9K — down 53% from $181K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ZVSA positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Cubist Systematic Strategies, opening a new position worth an estimated $22.1K. The largest seller was Anson Funds Management, exiting entirely with an estimated $145K sold.

  • 7 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q1 2024, up from 6 in Q4 2023.
  • Funds reported $84.9K of ZyVersa Therapeutics stock for Q1 2024, down 53% quarter-over-quarter.
  • 3 funds opened new ZyVersa Therapeutics positions in Q1 2024 and 2 closed out, a net change of +1 holder.
  • The largest ZyVersa Therapeutics buyer in Q1 2024 was Cubist Systematic Strategies, an estimated $22.1K added.
  • The largest ZyVersa Therapeutics seller in Q1 2024 was Anson Funds Management, an estimated $145K sold.

Based on aggregated 13F filings for Q1 2024.